Request Demo
AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
Clinical ResultDrug Approval
AstraZeneca (AZ) and Merck’s – known as MSD outside the US and Canada – Lynparza (olaparib) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a combination treatment for a subset of ovarian cancer patients.
AstraZeneca (AZ)n speMerckally recommended for NHS use alongside GenenteLynparzastolaparibcizumab) as a maintenance treaNational Institute for Health and Care Excellence (NICE)ian tube or primary peritoneal cancer, whose diseaseovarian cancer with homologous recombination deficiency (HRD)-positive status.
Eligible patients will also need to be in complete or partial resGenentechfirAvastin (bevacizumab)d chemotherapy.
Ovarian cancer is the sixth most common cancer in the UK, with 7,400 new cases of the disease diagnosed every year.
Ovarian cancer patients with advanced hicancerde ovarian cancer have HRD, when the body is unable to repair breaks in the DNA.
Given as a tablet, Lynparza works by inhibiting the PARP enzyme, which helps cells repair damaged DNA. By blocking this enzyme, PARP inhibitors prevent the DNA of cancer cells from being repaired, preventing them from growing and spreading.
NICE’s final draft Lynparza on the treatment was supported by positive results from the late-stage PAOLA-1 trial, in which the cPARP inhibitorsPARPnation reduced the risk of deatcancer7% in patients with HRD-positive advanced ovarian cancer.
Tom Keith-Roach, president, AZ UK, said: “We are delighted with this recommendation for women with advanced HRD-positive ovarian cancer.HRD-positive advanced ovarian cancer
“[Lynparza] was discovered aAZ UKveloped in England, and it is important that UK patients can routiadvanced HRD-positive ovarian canceres.”
LyLynparzaas been available on the NHS in England and Wales for patients with advanced ovarian cancer, and inherited BRCA1 or BRCA2 mutations who have stopped responding to treatment since January 2020.
Lynparza was also recommended by NICE in April this year for adults with HER2-advanced ovarian cancerly breast cancerBRCA1haveBRCA2rited faults in their BRCA1 or BRCA2 genes after surgery and chemotherapy, as well as for adults with previously treated hormone-relapsed metastatic prostate cancer who have the same BRCA mutations.
Keith-Roach said at the time: “This is a hard-won and extremely importantHER2-negative, high-risk early breast cancer follows on from the successful NICEBRCA1th tBRCA2logy assessment process.hormone-relapsed metastatic prostate cancer
"Innovative oncology medicines such as [Lynparza] often show effectiveness across multiple different cancer types and, in these situations, it’s essential that we continue to advance pricing and reimbursement pathways which support rapid and appropriate patient access.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.